Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer.
More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.
Review our LinkedIn community guidelines at http://bit.ly/AbbVieSocialGuidelines.
Location: United States, California, Sunnyvale
Member count: 1001-5000
Founded date: 1991
Investors 1
| Date | Name | Website |
| - | Asset Mana... | assetman.c... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 16.05.2018 | A big drug... | Thomson Reuters FILE PHOTO: P... | - | - | businessin... |
| 25.09.2015 | Former Pha... | This new round, ostensibly a S... | - | - | medcitynew... |
| 04.11.2014 | AstraZenec... | AstraZeneca and Pharmacyclics ... | - | - | cambridgen... |
| 06.06.2007 | Patients, ... | The first time you hear it, “e... | - | - | venturebea... |
| - | Former Pha... | Bay area immuno-oncology start... | - | - | medcitynew... |